1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Truqap Proves False For AstraZeneca

 
• By Elizabeth Cairns

The company’s attempt to move the AKT inhibitor into first-line triple-negative breast cancer proves a dud with the failure of the CAPItello-290 Phase III trial.      

AstraZeneca
• Source: Shutterstock: Elzbieta Krzysztof

Last year, AstraZeneca PLC’s Truqap (capivasertib) became the first AKT inhibitor to gain approval, with the UK giant intending to build on this by expanding into other settings. Now it has admitted that the next step was more of a stumble, with the failure of the drug’s pivotal trial in triple-negative breast cancer (TNBC).

Key Takeaways
  • The CAPItello-290 trial of Truqap in triple-negative breast cancer has failed, meaning the drug is stuck with a fairly narrow label for longer that AstraZeneca hoped.

CAPItello-290 found that Truqap plus paclitaxel showed no difference from paclitaxel and placebo in first-line locally advanced or metastatic TNBC...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.